POLOCAINE W/ LEVONORDEFRIN Drug Patent Profile
Which patents cover Polocaine W/ Levonordefrin, and what generic alternatives are available?
Polocaine W/ Levonordefrin is a drug marketed by Dentsply Pharm and is included in one NDA.
The generic ingredient in POLOCAINE W/ LEVONORDEFRIN is levonordefrin; mepivacaine hydrochloride. There is one drug master file entry for this compound. Additional details are available on the levonordefrin; mepivacaine hydrochloride profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for POLOCAINE W/ LEVONORDEFRIN?
- What are the global sales for POLOCAINE W/ LEVONORDEFRIN?
- What is Average Wholesale Price for POLOCAINE W/ LEVONORDEFRIN?
Summary for POLOCAINE W/ LEVONORDEFRIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | POLOCAINE W/ LEVONORDEFRIN at DailyMed |
US Patents and Regulatory Information for POLOCAINE W/ LEVONORDEFRIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dentsply Pharm | POLOCAINE W/ LEVONORDEFRIN | levonordefrin; mepivacaine hydrochloride | INJECTABLE;INJECTION | 089517-001 | Apr 14, 1988 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
POLOCAINE With Levonordefrin Market Dynamics, Patent Status, and Financial Trajectory
POLOCAINE with levonordefrin is a mature dental local anesthetic containing mepivacaine hydrochloride and levonordefrin, a vasoconstrictor. Its commercial profile is defined by established clinical use, generic competition, limited product differentiation, and low visibility into standalone revenue. The product has no biosimilar risk, no meaningful composition-of-matter patent runway, and limited potential for material price expansion.
The financial outlook is stable to declining in nominal terms unless supported by supply disruptions, price increases, or portfolio consolidation. Its value is more likely to arise from recurring dental-channel demand and manufacturing continuity than from exclusivity.
What is POLOCAINE with levonordefrin?
POLOCAINE with levonordefrin is an injectable dental anesthetic based on mepivacaine hydrochloride with levonordefrin at a concentration of 1:20,000. It is administered through dental cartridges for local or regional anesthesia during dental procedures.
| Product attribute | Details |
|---|---|
| Brand | POLOCAINE Dental |
| Active ingredient | Mepivacaine hydrochloride |
| Vasoconstrictor | Levonordefrin |
| Common concentration | Mepivacaine 2% with levonordefrin 1:20,000 |
| Dosage form | Injectable dental cartridge |
| Primary market | Dental local anesthesia |
| Regulatory category | Prescription drug |
| Biologic status | Not a biologic |
| Primary commercial use | Infiltration and nerve-block anesthesia in dentistry |
| Manufacturer history | Associated with the Dentsply dental-anesthetics portfolio |
| Market maturity | Mature, largely genericized |
The FDA label warns that levonordefrin can increase cardiovascular stimulation and that the product must be used with appropriate dose controls and patient screening.[1]
Who manufactures POLOCAINE with levonordefrin?
The product has historically been associated with Dentsply Sirona and its dental-products operations. Dentsply Sirona reports its business at segment and category levels rather than disclosing sales for individual mature anesthetic products.[2]
Public filings do not identify standalone annual revenue, gross margin, unit volume, or operating profit for POLOCAINE with levonordefrin. The product is therefore not independently modelable from company-reported financial statements.
What is the commercial position of the product?
POLOCAINE with levonordefrin occupies a narrow position within the dental anesthetic market. Dental practices can substitute among:
- Mepivacaine with levonordefrin
- Mepivacaine without a vasoconstrictor
- Lidocaine with epinephrine
- Articaine with epinephrine
- Prilocaine with epinephrine
- Bupivacaine for longer-duration procedures
The product’s differentiation is clinical familiarity and the pharmacologic profile of levonordefrin, not a proprietary delivery system or newly approved indication.
How large is the POLOCAINE with levonordefrin market?
No authoritative public source reports global or U.S. sales specifically for POLOCAINE with levonordefrin. Market research generally combines dental local anesthetics into broader categories and does not isolate individual legacy brands.
The addressable market has several characteristics:
| Market factor | Effect on POLOCAINE |
|---|---|
| Large installed base of dental practices | Supports recurring demand |
| High procedure volume | Limits demand volatility |
| Low switching costs among anesthetic products | Increases substitution risk |
| Generic availability | Pressures price and margins |
| Small cartridge-level product differentiation | Limits premium pricing |
| Dental distributor concentration | Increases channel dependence |
| Clinical familiarity | Supports retention |
| Levonordefrin-specific use | Limits total addressable volume relative to epinephrine products |
Demand is tied to dental procedure volume, practice employment trends, dental insurance utilization, and distributor inventory policies. It is less exposed to hospital formularies and specialty-pharmacy dynamics than oncology, immunology, or chronic-care medicines.
What is the financial trajectory for POLOCAINE with levonordefrin?
The likely financial trajectory is mature and low growth. Revenue can remain recurring, but long-term volume growth is constrained by generic substitution and competition from articaine and lidocaine products.
Base-case trajectory
The base case is flat-to-declining revenue in real terms:
- Dental procedure growth provides modest unit support.
- Generic competition limits price increases.
- Product-level sales remain too small for separate disclosure.
- Distributor purchasing and inventory cycles create quarterly volatility.
- Manufacturing and packaging costs determine margin more than research spending.
A mature injectable product can remain commercially useful even after its peak revenue period. Its economic value comes from low incremental commercial costs, established regulatory documentation, and access to dental distributors.
Upside case
Revenue could temporarily improve if:
- Competing products face shortages.
- The manufacturer secures favorable distributor contracts.
- Dental procedure volume increases faster than expected.
- The company raises prices without rapid substitution.
- A competitor exits the dental anesthetic market.
- Manufacturing reliability improves market share.
These factors would create share or price gains rather than structurally expand the category.
Downside case
The main downside risks are:
- Permanent substitution toward articaine or lidocaine with epinephrine.
- Levonordefrin supply interruptions.
- Manufacturing deviations or sterile-injectable quality issues.
- Distributor delisting.
- Dental practices standardizing on fewer anesthetic SKUs.
- Generic price competition.
- Reduced demand for vasoconstrictor formulations in cardiovascular-risk patients.
What patents protect POLOCAINE with levonordefrin?
No commercially significant composition-of-matter patent protection is expected to remain for mepivacaine hydrochloride or levonordefrin. Both active ingredients are long-established small molecules. The product’s commercial protection is therefore based on regulatory approval, manufacturing capability, supply reliability, and channel access rather than patent exclusivity.
| Protection category | Current commercial relevance |
|---|---|
| Composition-of-matter patent | No meaningful remaining protection expected |
| Original formulation patent | Historical only |
| Delivery-device patent | Limited relevance for standard dental cartridges |
| Method-of-use patent | Limited value for routine dental anesthesia |
| Manufacturing know-how | Potentially relevant |
| Sterile injectable quality systems | Material operational barrier |
| Distributor relationships | Material commercial barrier |
| Brand recognition | Modest defensive value |
A definitive patent-by-patent freedom-to-operate assessment would require review of the current FDA listing, assignment records, continuation history, and jurisdiction-specific prosecution files. The product’s age and generic market structure indicate that patent litigation is not the primary commercial risk.
When does POLOCAINE lose exclusivity?
POLOCAINE has already passed the period in which conventional drug exclusivity would drive market economics. Any original new-drug exclusivity or early patent protection would have expired decades ago.
The relevant distinction is between legal exclusivity and practical market access:
- Legal exclusivity: no meaningful current exclusivity is apparent from the product’s mature status.
- Regulatory approval: continues as long as the applicable approved product remains active and compliant.
- Commercial access: depends on manufacturing, supply, wholesaler contracts, and dentist purchasing behavior.
- Brand value: may persist despite generic competition.
FDA exclusivity periods are generally tied to approval of new chemical entities, certain supplements, orphan products, pediatric studies, or qualified infectious-disease products. A legacy mepivacaine product does not fit the profile of a product with current NCE-style exclusivity.[3]
What is the Orange Book status of POLOCAINE?
The FDA Orange Book identifies approved drug products and, where applicable, listed patents and exclusivity information. Mature local anesthetics may appear through legacy NDA or abbreviated-approval records, but an Orange Book listing does not by itself establish current commercial exclusivity.[4]
For POLOCAINE with levonordefrin, the practical Orange Book conclusion is:
| Orange Book issue | Commercial assessment |
|---|---|
| Active NCE exclusivity | Not expected |
| Active pediatric exclusivity | Not expected |
| Active orphan exclusivity | Not applicable |
| Current patent-based barrier | Not expected to be material |
| Paragraph IV exposure | Low strategic significance |
| Generic substitution | Established market reality |
Which companies are challenging POLOCAINE?
The product is challenged primarily through market substitution rather than high-profile patent litigation. Competing manufacturers and product families include suppliers of:
- Generic mepivacaine with vasoconstrictor
- Generic mepivacaine without vasoconstrictor
- Articaine with epinephrine
- Lidocaine with epinephrine
- Prilocaine with epinephrine
Septodont is a major dental local-anesthetic competitor globally, with products such as SEPTANEST and other cartridge-based anesthetics. Dentsply Sirona also participates in dental anesthetics through products including Xylocaine-related and articaine-related commercial channels, depending on market and product ownership structure.[5]
The most important competitive issue is not a Paragraph IV filing. It is whether dentists and distributors treat POLOCAINE with levonordefrin as a required SKU or as one interchangeable option within a broader anesthetic basket.
What formulation and manufacturing barriers protect the product?
The principal barriers are operational.
Formulation and dosage-form considerations
POLOCAINE with levonordefrin must maintain:
- Sterility
- Chemical stability
- Dose uniformity
- Cartridge integrity
- Compatibility with dental syringes
- Controlled vasoconstrictor concentration
- Acceptable storage conditions
- Reliable packaging and labeling
Dental cartridges are relatively standardized, but sterile injectable manufacturing is more demanding than production of oral solid dosage forms. A new entrant must qualify filling, cartridge, packaging, testing, release, and distribution processes.
Manufacturing risks
The most material manufacturing risks are:
- Sterile-facility capacity constraints
- Component shortages
- Glass-cartridge availability
- Quality-control failures
- Labeling or packaging errors
- Temperature or storage excursions
- Limited alternate manufacturing sites
These barriers can support short-term pricing power during shortages. They do not create durable exclusivity because competitors can generally develop equivalent products if the market opportunity justifies the investment.
What FDA regulatory issues affect POLOCAINE?
FDA risk is primarily related to manufacturing compliance, labeling, and supply continuity rather than clinical development.
The product label identifies cardiovascular warnings associated with levonordefrin and cautions regarding dosage, contraindications, and interactions with certain medicines.[1] Regulatory events that could affect commercial performance include:
- Manufacturing inspection findings
- Product recalls
- Sterility failures
- Changes in cartridge components
- Labeling revisions
- Drug-shortage listings
- Discontinuation or withdrawal of an approved presentation
No biosimilar pathway applies. Mepivacaine and levonordefrin are small-molecule active ingredients, so the relevant competitive routes are abbreviated new drug applications, legacy generic approvals, and conventional drug-product approvals rather than 351(k) biosimilar applications.
What patent litigation and settlement risk exists?
Patent litigation risk appears low relative to the risks facing newer pharmaceutical products. The product is a legacy anesthetic with no evident high-value patent estate driving a current settlement market.
A Paragraph IV challenge would have limited economic significance unless it targeted a specific active formulation, device, or manufacturing patent. A generic entrant would more likely compete through approval, pricing, and distribution than through a settlement tied to delayed market entry.
No material POLOCAINE-specific settlement agreement is broadly associated with the product’s current market position. The absence of high-profile litigation is consistent with a mature genericized market.
How does POLOCAINE compare with competing dental anesthetics?
| Product type | Primary advantage | Main limitation | Competitive effect on POLOCAINE |
|---|---|---|---|
| Mepivacaine with levonordefrin | Familiar formulation and vasoconstrictor profile | Narrower use and cardiovascular considerations | Direct substitute |
| Plain mepivacaine | Avoids vasoconstrictor exposure | Shorter duration or greater bleeding-control limitations | Direct substitute |
| Articaine with epinephrine | Strong adoption in many dental markets | Epinephrine-related considerations | Major share pressure |
| Lidocaine with epinephrine | Broad familiarity and availability | Potentially shorter or less differentiated clinical profile | High substitution risk |
| Prilocaine with epinephrine | Established dental use | Methemoglobinemia-related warnings | Secondary substitute |
| Bupivacaine | Long duration | Slower onset and different procedure profile | Limited overlap |
POLOCAINE competes best where a dentist values mepivacaine’s clinical characteristics and specifically wants levonordefrin. It competes poorly on price if the buyer views all cartridges as interchangeable.
What generic launch scenarios exist?
A new generic entrant would not need to overcome meaningful patent barriers. Its main launch requirements would be FDA approval, validated sterile manufacturing, supply reliability, and distributor access.
| Scenario | Likely market result |
|---|---|
| One new generic entrant | Moderate price pressure |
| Multiple generic entrants | Rapid erosion in unit price and share |
| Existing supplier shortage | Temporary POLOCAINE volume recovery |
| Brand discontinuation | Switching to generic mepivacaine or alternative anesthetics |
| Distributor consolidation | Greater price pressure and reduced SKU flexibility |
| Manufacturing failure | Immediate revenue loss and possible dentist substitution |
The probability of a sudden, patent-driven generic launch is lower than the probability of gradual share erosion through existing alternatives.
What revenue exposure does POLOCAINE create for its owner?
POLOCAINE is unlikely to represent a material percentage of the owner’s consolidated revenue. Dentsply Sirona generates sales across dental consumables, equipment, technology, and specialty products, while individual legacy anesthetic brands are not separately reported in its public financial statements.[2]
The financial exposure is therefore asymmetric:
- Absolute revenue exposure: likely limited.
- Margin exposure: potentially higher than revenue exposure if production is low volume or inefficient.
- Supply-chain exposure: meaningful if the product is part of a broader anesthetic portfolio.
- Customer-retention value: modest but recurring.
- Litigation exposure: low.
- Strategic value: primarily portfolio completeness and dental-channel presence.
How strong is the POLOCAINE patent estate?
The patent estate is weak as a current source of exclusivity but may be irrelevant to commercial continuity.
| Patent-strength factor | Assessment |
|---|---|
| Remaining compound exclusivity | Very weak or nonexistent |
| Formulation differentiation | Limited |
| Method-of-use protection | Limited |
| Device protection | Limited |
| Manufacturing know-how | Moderate operational value |
| Regulatory moat | Moderate for sterile injectable compliance |
| Brand and channel position | Moderate |
| Litigation leverage | Low |
| Generic-entry deterrence | Low |
The product’s defensibility depends on execution. A manufacturer that maintains reliable supply and distributor coverage can retain business without a strong patent estate.
Key Takeaways
- POLOCAINE with levonordefrin is a mature dental injectable containing mepivacaine hydrochloride and levonordefrin.
- No meaningful current composition-of-matter or regulatory exclusivity is expected.
- Its market is exposed to generic mepivacaine, articaine, lidocaine, and other dental anesthetics.
- Standalone revenue and profit are not publicly disclosed.
- The likely financial trajectory is flat to declining in real terms, with temporary upside during competitor shortages.
- Sterile manufacturing, cartridge supply, quality compliance, and distributor access matter more than patents.
- Biosimilar risk does not apply.
- Paragraph IV litigation and settlement risk appear low.
- The main commercial risk is substitution, not a patent cliff.
- The product’s strategic value is recurring dental-channel demand and portfolio continuity.
FAQs about POLOCAINE with levonordefrin
Is POLOCAINE with levonordefrin still commercially relevant?
Yes. It remains relevant as a legacy dental anesthetic, although its market position is constrained by generic alternatives and competing vasoconstrictor formulations.
Is levonordefrin the same as epinephrine?
No. Levonordefrin and epinephrine are different vasoconstrictors with different pharmacologic profiles. Dental products containing either agent require product-specific labeling and clinical judgment.
Can dentists substitute articaine for POLOCAINE?
Articaine may be used as an alternative in appropriate dental procedures, but substitution depends on clinical requirements, patient factors, dentist preference, and local product availability.
Does POLOCAINE have biosimilar competition?
No. POLOCAINE contains small-molecule active ingredients. Competition occurs through generic drug products and alternative local anesthetics, not biosimilars.
What would most improve POLOCAINE revenue?
The strongest near-term drivers would be reliable supply, favorable distributor placement, temporary shortages affecting competing products, and retention of dentists who prefer mepivacaine with levonordefrin.
References
-
U.S. Food and Drug Administration. (n.d.). POLOCAINE Dental: Mepivacaine hydrochloride and levonordefrin injection prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
-
Dentsply Sirona Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. https://investor.dentsplysirona.com/
-
U.S. Food and Drug Administration. (n.d.). Drug development and review definitions: Exclusivity. https://www.fda.gov/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
Septodont. (n.d.). Dental local anesthetics and injectable products. https://www.septodont.com/
More… ↓
